Combination of LABA + inhaled glucocorticoid safe in asthma

June 28, 2018

(HealthDay)—Compared to treatment with an inhaled glucocorticoid alone, combination therapy with a long-acting β2-agonist (LABA) and an inhaled glucocorticoid is not associated with a significantly higher risk of serious asthma-related events, according to a study published online June 27 in the New England Journal of Medicine.

William W. Busse, M.D., from the University of Wisconsin School of Medicine and Public Health in Madison, and colleagues performed a combined analysis of four trials comparing an inhaled glucocorticoid plus a LABA with an inhaled glucocorticoid alone in adolescents and adults with asthma.

The researchers identified three asthma-related intubations (two in the inhaled-glucocorticoid , one in the group) and two asthma-related deaths (both in the combination- group) in four patients among the 36,010 patients in the intention-to-treat study. In a secondary analysis of serious asthma-related events, 0.6 percent of 18,006 patients in the inhaled-glucocorticoid group and 0.66 percent of 18,004 in the combination-therapy group had at last one composite event (relative risk in the combination therapy group, 1.09; 95 percent confidence interval, 0.83 to 1.43; P = 0.55); 11.7 and 9.8 percent, respectively, had at least one asthma exacerbation (relative risk, 0.83; 95 percent confidence interval, 0.78 to 0.89; P < 0.001).

"Combination therapy with a LABA plus an inhaled glucocorticoid did not result in a significantly higher risk of serious asthma-related events than treatment with an inhaled glucocorticoid alone but resulted in significantly fewer asthma exacerbations," the authors write.

Several authors disclosed ties to the pharmaceutical and medical device industries.

Explore further: Study shows combination drug therapy for asthma patients is safe

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Study shows combination drug therapy for asthma patients is safe

August 31, 2016
A post-marketing safety study mandated by the U.S. Food and Drug Administration has shown that a combination drug therapy for the treatment of asthma is safe and effective.

FDA removes boxed warning from certain asthma medications

December 26, 2017
(HealthDay)—New evidence regarding safety is spurring the U.S. Food and Drug Administration to remove a Boxed Warning from certain inhaled medications used to treat asthma and chronic obstructive pulmonary disease.

ERS: Mepolizumab is glucocorticoid-sparing in asthma

September 9, 2014
(HealthDay)—For patients with eosinophilic asthma, mepolizumab has a glucocorticoid-sparing effect and reduces exacerbations when administered intravenously or subcutaneously, according to two studies published online Sept. ...

Inhaled steroids may increase pneumonia risk in people with asthma

April 20, 2017
Use of inhaled corticosteroids was linked with an increased risk of pneumonia in a study of individuals with asthma.

New research shows asthma drug's effectiveness over usual care alone

September 13, 2017
A new study co-authored by the University of Plymouth and published in The Lancet shows how an asthma drug was more effective at improving a patient's asthma control compared with their usual care.

Leukotriene receptor antagonist monotherapy ups asthma control

September 22, 2015
(HealthDay)—As monotherapy, leukotriene-receptor antagonists (LTRAs) improve asthma control versus placebo, according to a review and meta-analysis published online Sept. 22 in the Annals of Internal Medicine.

Recommended for you

Immunity connects gut bacteria and aging

November 13, 2018
Over the years, researchers have learned that the different populations of bacteria that inhabit the gut have significant effects on body functions, including the immune system. The populations of gut bacteria are sometimes ...

An enzyme in immune cells plays essential role in host defense against tuberculosis

November 13, 2018
Using freshly resected lung tissue from 21 patients and two distinct mouse models, tuberculosis researchers at the University of Alabama at Birmingham and the Africa Health Research Institute, or AHRI, have identified a protein ...

Probiotics increase bone volume in healthy mice

November 13, 2018
A widely-used probiotic stimulates bone formation in young female mice, according to a study published November 13th in the journal Immunity. In response to treatment with Lactobacillus rhamnosus GG (LGG), other intestinal ...

Study shows changes in histone methylation patterns in nutritionally stunted children

November 13, 2018
An international team of researchers has found changes in histone methylation patterns in nutritionally stunted children. In their paper published in Proceedings of the National Academy of Sciences, the group describes their ...

New clues to the origin and progression of multiple sclerosis

November 13, 2018
Mapping of a certain group of cells, known as oligodendrocytes, in the central nervous system of a mouse model of multiple sclerosis (MS), shows that they might have a significant role in the development of the disease. The ...

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.